10,893 Shares in Royalty Pharma plc (NASDAQ:RPRX) Acquired by Corton Capital Inc.

Corton Capital Inc. acquired a new position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 10,893 shares of the biopharmaceutical company's stock, valued at approximately $278,000.

A number of other institutional investors also recently bought and sold shares of RPRX. Crestline Management LP raised its stake in shares of Royalty Pharma by 360.8% during the 4th quarter. Crestline Management LP now owns 101,578 shares of the biopharmaceutical company's stock worth $2,591,000 after buying an additional 79,532 shares during the last quarter. Cutter Capital Management LP increased its holdings in Royalty Pharma by 15.0% during the 4th quarter. Cutter Capital Management LP now owns 764,859 shares of the biopharmaceutical company's stock valued at $19,512,000 after acquiring an additional 100,000 shares in the last quarter. Bridgefront Capital LLC acquired a new position in Royalty Pharma during the fourth quarter worth about $311,000. Balyasny Asset Management L.P. purchased a new stake in shares of Royalty Pharma in the fourth quarter valued at about $1,524,000. Finally, Baird Financial Group Inc. acquired a new stake in shares of Royalty Pharma in the fourth quarter valued at approximately $1,586,000. 54.35% of the stock is currently owned by hedge funds and other institutional investors.

Royalty Pharma Stock Performance

Shares of NASDAQ RPRX opened at $32.11 on Wednesday. The company has a 50-day simple moving average of $32.42 and a 200-day simple moving average of $29.67. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. The company has a market cap of $18.51 billion, a PE ratio of 22.14, a price-to-earnings-growth ratio of 2.31 and a beta of 0.49. Royalty Pharma plc has a 12 month low of $24.05 and a 12 month high of $34.20.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. On average, equities analysts anticipate that Royalty Pharma plc will post 4.49 earnings per share for the current year.

Royalty Pharma Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be given a dividend of $0.22 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $0.88 annualized dividend and a yield of 2.74%. Royalty Pharma's dividend payout ratio (DPR) is presently 60.69%.

Analyst Upgrades and Downgrades

Separately, Citigroup reaffirmed a "buy" rating on shares of Royalty Pharma in a research note on Friday, March 28th. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $42.50.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

Want to see what other hedge funds are holding RPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Royalty Pharma plc (NASDAQ:RPRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.